Adasuve Inhalant Approved for Agitation in Bipolar, Schizophrenia

Adasuve (loxapine) Inhalation Powder was approved late last week by the U.S. Food and Drug Administration (FDA) for the treatment of agitation in bipolar I disorder and schizophrenia in adults.

Adasuve combines a proprietary delivery system with the antipsychotic drug, loxapine. The Staccato delivery system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in rapid systemic delivery and absorption of a drug, similar to an asthma inhaler. Adasuve is manufactured by Alexza Pharmaceuticals.

Adasuve (loxapine) Inhalation Powder comes in a 10 mg form.

Agitation, according to the company’s news release, is a serious problem that can present in a number of psychiatric disorders, including schizophrenia and bipolar I disorder. Of the estimated 3.2 million patients treated for schizophrenia or bipolar I disorder in the U.S., about 90 percent suffer from some type of agitation in their lifetime. The agitation can be due to the natural course of underlying disease or because of non-compliance with chronic medication. Most patients average 11 to 12 episodes of agitation each year.

By PsychCentral

Full Article

Speak Your Mind